Plasma metabolomic and lipidomic alterations associated with COVID-19.
Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, Liu W, Huang M, Yu Y, Yang Q, Zhu T, Xu J, Mu J, Wang Y, Wang H, Tang T, Ren Y, Wu Y, Lin SH, Qiu Y, Zhang DY, Shang Y, Zhou X. · 2020
Read Plasma metabolomic and lipidomic alterations associated with COVID-19. by Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, Liu W, Huang M, Yu Y, Yang Q, Zhu T, Xu J, Mu J, Wang Y, Wang H, Tang T, Ren Y, Wu Y, Lin SH, Qiu Y, Zhang DY, Shang Y, Zhou X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7197563.txt.
Introduction
Wu and co-authors profile small molecules and fats in the blood of COVID-19 patients. Their study appeared in National Science Review. Symptoms of the disease range from mild to fatal. The body-wide chemical changes behind that range were barely understood. The team ran targeted metabolomic and lipidomic tests on patient plasma.
The chemical patterns tracked closely with how the illness progressed. Changes in malic acid pointed to disturbed energy metabolism. Shifts in carbamoyl phosphate suggested liver strain. Fat molecules also differed between mild, severe, and fatal cases. The results show the infection reshapes whole-body metabolism. Such profiles might help doctors judge a patient's course. They also hint at which organs suffer hidden stress.
Catalog record
| CREATOR | Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, Liu W, Huang M, Yu Y, Yang Q, Zhu T, Xu J, Mu J, Wang Y, Wang H, Tang T, Ren Y, Wu Y, Lin SH, Qiu Y, Zhang DY, Shang Y, Zhou X. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Plasma metabolomic and lipidomic alterations associated with COVID-19 By Di Wu, Ting Shu, Xiaobo Yang, Jian-Xin Song, Mingliang Zhang, Chengye Yao, Wen Liu, Muhan Huang, Yuan Yu, Qingyu Yang, Tingju Zhu, Jiqian Xu Published in: National Science Review DOI: 10.1093/nsr/nwaa086 ABSTRACT Abstract The pandemic of the coronavirus disease 2019 (COVID-19) has become a global public health crisis. The symptoms of COVID-19 range from mild to severe, but the physiological changes associated with COVID-19 are barely understood. In this study, we performed targeted metabolomic and lipidomic analyses of plasma from a cohort of patients with COVID-19 who had experienced different symptoms. We found that metabolite and lipid alterations exhibit apparent correlation with the course of disease in these patients, indicating that the development of COVID-19 affected their whole-body metabolism. In particular, malic acid of the TCA cycle and carbamoyl phosphate of the urea cycle result in altered energy metabolism and hepatic dysfunction, respectively. It should be noted that carbamoyl phosphate is profoundly down-regulated in patients who died compared with patients with mild symptoms. And, more importantly, guanosine monophosphate (GMP), which is mediated not only by GMP synthase but also by CD39 and CD73, is significantly changed between healthy subjects and patients with COVID-19, as well as between the mild and fatal cases. In addition, dyslipidemia was observed in patients with COVID-19. Overall, the disturbed metabolic patterns have been found to align with the progress and severity of COVID-19. This work provides valuable knowledge about plasma biomarkers associated with COVID-19 and potential therapeutic targets, as well as an important resource for further studies of the pathogenesis of COVID-19. Keywords: SARS-CoV-2, COVID-19, metabolome, lipidome INTRODUCTION The outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic by the World Health Organization (WHO). Up to the date of April 21, 2020, there are around 2.4 million confirmed COVID-19 cases and it has caused 162 956 deaths worldwide according to the WHO situation report. Based on a recent study of 44 672 confirmed COVID-19 cases up to February 11 by the Chinese Center for Disease Control and Prevention, over 19% of patients with COVID-19 developed severe or critical conditions [1]. The global fatality rate is around 4.8% in all the confirmed cases until March 31, and has even reached 10% in some developed countries, probably because of greater populations of elderly people [2]. The main organ attacked by SARS-CoV-2 is the lower respiratory tract, with some patients developing life-threatening acute respiratory distress syndrome (ARDS). Attacks have also been found or proposed on liver, muscle, gastrointestinal tract, lymph node, and heart by SARS-CoV-2 [3–6]. On the other hand, although more than 80% of patients with COVID-19 experienced only mild symptoms, it has been found that the conditions can rapidly progress from mild to severe, particularly in the absence of adequate medical care. Moreover, the mortality rate of COVID-19 in critically ill cases can be over 60%, posing great pressure on treatment [7]. However, the physiological changes associated with COVID-19 under different symptomatic conditions are barely understood. Metabolites and lipids are major molecular constituents in human plasma. During critical illness, metabolic and lipid abnormalities are commonly observed, which are believed to contribute to physiology and pathology. Moreover, previous studies have demonstrated dramatic alterations of metabolome and lipidome in human plasma caused by various diseases including viral infections, such as Ebola virus disease [8,9]. Here, we performed targeted metabolomic and lipidomic profiles of plasma samples collected from a cohort of patients with COVID-19, including fatalities from COVID-19 and survivors recovered from mild or severe symptoms. Our findings here show that many of the metabolite and lipid alterations, particularly those associated with hepatic functions, align with the progress and severity of the disease, which could provide valuable knowledge about plasma biomarkers associated with COVID-19 as well as potential therapeutic targets, and shed light on the pathogenesis of COVID-19. RESULTS Study design and patients Blood samples were harvested at Wuhan Jinyintan Hospital from patients with COVID-19, as confirmed by laboratory nucleic acid test of SARS-CoV-2 infection. Serial samples were collected over the course of disease from nine patients with fatal (F) outcome (F1–F4), 11 patients diagnosed as having severe (S) symptoms (S1–S2), and 14 patients diagnosed as having mild (M) symptoms (M1–M2) (Table S1). Of note, all the patients in the severe (S) and mild (M) groups had survived from COVID-19 and been discharged from the hospital. F1 represents the first samples collected from patients with COVID-19 who had a fatal outcome, while F4 represents the last samples before additional samples could be collected. S1 and M1 represent the samples during the disease peak of the patients in the severe or mild groups, respectively, as determined based on the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th edition) published by the National Health Commission of China [10], while S2 and M2 represent the last samples collected from patients in each group before the patients were discharged from the hospital. For comparison, the blood samples from 10 healthy volunteers, whose throat swabs and serological testing were negative for SARS-CoV-2, were collected. The hydrophilic and hydrophobic metabolites were extracted from each plasma sample, respectively, and measured using a liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) system. Metabolite identification was conducted with use of a home-made database with retention time and ion pairs. For those metabolites without authentic standards in our database, we used MS/MS spectra to search against public databases to improve confidence in metabolite identification. The orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to discriminate metabolomic profiles between the groups of patients with COVID-19 and healthy people (Figs S1–S4). In total, 431 metabolites and 698 lipids were identified and quantified, and both metabolome and lipidome showed dramatic alterations in the plasma of patients with COVID-19 (Tables S2 and S3). Plasma metabolomic alterations associated with clinical symptoms of COVID-19 For different courses of fatalities from COVID-19 (F1–F4), we analyzed the metabolites that underwent significant change [F4 vs. H, log2fold change (FC)>1 typically P < 0.05]. For F vs. H, 87 of the total 431 metabolites were significantly different (P < 0.05) at F1, while the number of significantly altered metabolites increased to 162 at F4 in the fatalities; and most of the changes were down-regulated (Table S2). We found a positive correlation between the alteration of metabolites and the course of disease deterioration in patients with a fatal outcome (Fig. 1A and Table S4), indicating that the development of disease affects the metabolism of metabolites. [Figure: COVID-19 signatures in the plasma metabolome. Selected average plasma metabolite expression levels and associated P values for the COVID-19 fatality patient group vs. the healthy volunteer group (A), and severe or mild vs. healthy groups (B). F, fatalities; first, second, third and fourth samples, F1, F2, F3 and F4. S, severe patients; first and second samples, S1 and S2. M, mild patients; first and second samples, M1 and M2.] We also profiled the metabolites in the different courses of severe and mild COVID-19 (S1 and S2; M1 and M2), and analyzed those that underwent significant change [S1 vs. H, log2FC>1, typically P < 0.05; M1 vs. H, log2FC>1, typically P < 0.05] (Fig. 1B and Table